Acute Pancreatitis Associated with Angiotensin II Receptor Antagonists

2002 ◽  
Vol 36 (12) ◽  
pp. 1883-1886 ◽  
Author(s):  
Alexander A Fisher ◽  
Mark L Bassett
Keyword(s):  
Acute Pancreatitis ◽  
Angiotensin Ii ◽  
Causality Assessment ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Angiotensin Ii Receptor Antagonist ◽  
Receptor Antagonists ◽  
Case Summary ◽  
Treatment Of Hypertension ◽  
Combination Formulation

OBJECTIVE: To report a case of acute pancreatitis in a patient receiving a combination formulation of irbesartan and hydrochlorothiazide (HCTZ). CASE SUMMARY: A 33-year-old white woman developed acute pancreatitis 10 days after starting irbesartan 300 mg and hydrochlorothiazide 12.5 mg for treatment of hypertension. Her symptoms disappeared and serum concentrations of lipase and amylase returned to normal 2 days after irbesartan/HCTZ was discontinued. A search of MEDLINE (1990–September 2002) and the Australian Adverse Drug Reaction Advisory Committee database revealed 1 additional case of pancreatitis associated with irbesartan/HCTZ and 3 cases of pancreatitis associated with losartan. DISCUSSION: An objective causality assessment indicates that it is probable that pancreatitis was caused by the angiotensin II receptor antagonist irbesartan (and the same is probably true for losartan). It is less likely that the hydrochlorothiazide in irbesartan/HCTZ caused pancreatitis in our patient since the dose was lower than that usually associated with thiazide-induced pancreatitis. Angiotensin II receptors are thought to be important in regulation of pancreatic secretion and microcirculation, but the mechanism of pancreatitis induced by angiotensin II receptor antagonists remains unclear. CONCLUSIONS: Clinicians should be aware that irbesartan/HCTZ or losartan may cause acute pancreatitis. If abdominal pain develops, the medication should be discontinued and the patient investigated for acute pancreatitis.

scholarly journals Long-Term Consequences of Fetal Angiotensin II Receptor Antagonist Exposure

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
K. Wegleiter ◽  
M. Waltner-Romen ◽  
R. Trawoeger ◽  
U. Kiechl-Kohlendorfer ◽  
E. Griesmaier
Keyword(s):  
Angiotensin Ii ◽  
Receptor Antagonist ◽  
Neonatal Period ◽  
Clinical Symptoms ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Angiotensin Ii Receptor Antagonist ◽  
Receptor Antagonists

Fetal angiotensin II receptor antagonist exposure is associated with major complications and even death when administered during pregnancy. Neonates frequently require intensive care treatment, and mortality is high. Despite this well-known risk potential, a considerable number of women still receive angiotensin II receptor antagonists during pregnancy to treat arterial hypertension. Although clinical symptoms in the neonatal period are well described, few reports address long-term follow-up after fetal exposure to angiotensin II receptor antagonists. We here report on a patient who was unwittingly exposed to olmesartan medoxomil during pregnancy. After birth, the neonate presented with mild clinical symptoms, mainly affecting the kidneys. However, neurodevelopmental follow-up revealed a delay in motor development with muscular hypotonia and failure to thrive at age 2 years. This case highlights the fact that, despite not causing neurological symptoms in the neonatal period, fetal angiotensin II receptor antagonist exposure during pregnancy might lead to neurodevelopmental impairment in later life.

scholarly journals ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HYPERTENSION: PERSPECTIVES FOR CLINICAL USE

2013 ◽  
Vol 19 (2) ◽  
pp. 117-124 ◽  
Author(s):  
N. G. Poteshkina ◽  
G. V. Selivanova ◽  
T. Zh. Zhalsaraev
Keyword(s):  
Angiotensin Ii ◽  
Antihypertensive Drugs ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Review Of Literature ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Receptor Antagonists ◽  
Treatment Of Hypertension ◽  
Antiarrhythmic Effects

The review of literature presents evidence of the relevance of the wider application of angiotensin II receptor antagonists in the treatment of cardiovascular diseases. The advantages of this class of antihypertensive drugs on the effect on blood pressure and regression of target organ damage in patients with hypertension. The data on nephroprotective, neuroprotective, antiarrhythmic effects of angiotensin II receptor antagonists, as well as the opportunity of effective correction of the metabolic abnormalities are presented.

scholarly journals Type 1 angiotensin II receptor antagonists in cardiovascular diseases: Valsartan

2011 ◽  
Vol 17 (4) ◽  
pp. 325-332 ◽  
Author(s):  
Y. V. Sviryaev ◽  
N. E. Zvartau
Keyword(s):  
Angiotensin Ii ◽  
Cardiovascular Diseases ◽  
Receptor Antagonist ◽  
Antihypertensive Effect ◽  
Clinical Use ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Angiotensin Ii Receptor Antagonist ◽  
Receptor Antagonists

The article focuses on antihypertensive effect, organoprotection properties and clinical use of angiotensin II receptor antagonist valsartan in patients with cardiovascular diseases.

scholarly journals DAMAGE OF RENAL FUNCTION AND DYNAMICS OF DYSLIPIDEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH INSUFFICIENT GLYCEMIC COMPENSATION UNDER CONDITION OF CORRECTION OF HYPERTENSION WITH ANGIOTENSIN II RECEPTOR ANTAGONISTS

2014 ◽  
pp. 30-36
Author(s):  
N.O. Pertseva
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Standard Treatment ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Receptor Antagonists ◽  
Treatment Of Hypertension

Damage of renal function and dynamics of dyslipidemia in patients with type 2 diabetes mellitus with insufficient glycemic compensation under condition of correction of hypertension with angiotensin II receptor antagonists   Introduction. Need to be studied issues related to the dynamics of nephropathic and dyslipidemic disorders on the background of long-term treatment of hypertension with using angiotensin II receptor antagonists in patients with type 2 diabetes mellitus. Materials and methods. The treatment and examination of 87patients with type 2 diabetes mellitus with insufficient glycemic compensation and hypertension. The dynamics of nephropathic and dyslipidemic disorders during 1 year of treatment was studied. Results and discussion. On the background of the standard treatment of hypertension occur regression of microalbuminuria in 32.3% of patients, as well as normalization of concentrations of low density lipoprotein cholesterol and triglyceride levels after 1 year of treatment. Antihypertensive therapy with the use of angiotensin II receptor antagonists significantly more effective than standard treatment policy to influence the development of dyslipidemia. Conclusion. After 6 months of treatment on the background of normalization dyslipidemic disorders and nephropathic disorders use ofangiotensin II receptor antagonists followed by regression of microalbuminuria in 54.7% ofpatients.

Investigation Planning and Bioequivalence evaluation of Angiotensin II Receptor Antagonists

2019 ◽  
Vol 53 (8) ◽  
pp. 680-684
Author(s):  
D. P. Romodanovskii ◽  
D. V. Goryachev ◽  
A. L. Khokhlov ◽  
A. N. Miroshnikov
Keyword(s):  
Angiotensin Ii ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Receptor Antagonists

ChemInform Abstract: Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy

ChemInform ◽  
2010 ◽  
Vol 27 (21) ◽  
pp. no-no
Author(s):  
R. R. WEXLER ◽  
W. J. GREENLEE ◽  
J. D. IRVIN ◽  
M. R. GOLDBERG ◽  
K. PRENDERGAST ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Antihypertensive Therapy ◽  
Next Generation ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Receptor Antagonists
Sign in / Sign up

Export Citation Format

Share Document